Reviews focusing on semaglutide specifically [65] and broader examinations of GLP-1 RA mechanisms and clinical data have consistently concluded that these agents represent important therapeutic advances
Most published studies have focused on semaglutide because it currently has the largest user base, which makes statistical analysis easier
GLP-1 medications may be worth discussing with your provider if you have PMOS and one or more of these patterns: Insulin resistance, prediabetes, type 2 diabetes, or elevated fasting insulin
Finally, evaluation of small molecule GLP-1R agonists beyond their effectiveness in T2DM and obesity presents a significant area of opportunity
Peer review Peer review information Nature Metabolism thanks Hamlet Gasoyan, Jason Halford and the other, anonymous, reviewer(s) for their contribution to the peer review of this work
This is a real consideration, not a minor footnote